Myriad Genetics Surges 29% After $210M Prenatal Unit Sale to Labcorp

Event Analysis

As reported by Myriad Genetics' SEC Form 8-K and confirmed by RTTNews, Myriad Genetics, Inc. (NASDAQ: MYGN) signed a definitive agreement on October 19, 2026, to sell its Prenatal Health business to Laboratory Corporation of America (NYSE: LH) for $210 million in cash plus the value of transferred inventory at closing. The deal includes the Prequel Prenatal Screen, Foresight Carrier Screen, SneakPeek Early Gender Test, and FirstGene 4-in-1 Prenatal Screen. The transaction is expected to close by early 2027, subject to regulatory clearance.

The 29.1% surge in MYGN shares to $5.45 — with premarket gains exceeding 20%, per GuruFocus — signals that investors view the $210 million cash infusion as a meaningful balance-sheet event for a company whose stock had been trading at deeply depressed levels. The sale price effectively validates the prenatal portfolio's standalone value and removes it from a business mix that the market had arguably been discounting. This is a portfolio simplification story: Myriad is repositioning itself around its core molecular diagnostics and precision medicine operations, shedding a consumer-facing prenatal segment that Labcorp can more efficiently scale through its existing laboratory infrastructure.

For Labcorp, the strategic rationale is distribution leverage. According to market commentary cited by GuruFocus, Labcorp projects approximately $160 million of first-year revenue from the acquired assets, with modest earnings accretion expected by year two. This fits neatly into the broader M&A acquisition wave reshaping specialty diagnostics — larger platforms absorbing niche testing assets to improve utilization and physician access. The deal also reinforces the energy, pharma & tech acquisition wave as healthcare consolidation continues to accelerate in 2026.

What distinguishes this deal from typical asset sales is the magnitude of the price reaction relative to Myriad's pre-announcement market cap. A $210 million cash deal producing a near-30% single-day move suggests the market was either deeply skeptical of the prenatal unit's value or had underpriced Myriad's strategic options — both of which create meaningful read-throughs for other subscale diagnostics companies holding undervalued specialty portfolios.

What This Means for Traders

For MYGN, the immediate price action reflects a classic acquisition-driven repricing event. The bullish case rests on three pillars: $210 million in cash strengthening a previously strained balance sheet, reduced operational complexity, and the market re-rating the remaining precision medicine business as a cleaner asset. Key risks before the early-2027 close include regulatory delays and the question of what Myriad's revenue and margin profile looks like post-divestiture. Traders should monitor whether the initial gap holds or fades as the market digests the earnings impact of losing the prenatal revenue stream.

For Labcorp (LH), the deal is likely a modest positive — the purchase price is small relative to Labcorp's overall business, but the projected $160M first-year revenue contribution and accretion timeline support a neutral-to-slightly-bullish read. Sector-wide, the transaction may prompt investors to reassess other standalone diagnostics names with specialty testing assets that could attract similar strategic interest. Broader indices such as the S&P 500 and NASDAQ 100 are unlikely to see material impact — this is an idiosyncratic healthcare event, not a macro catalyst.

This announcement hit premarket, meaning the initial gap was already priced into the open. Traders evaluating MYGN now must weigh post-gap momentum against the closing risk inherent in any deal pending regulatory approval — a dynamic well-covered in the acquisition arbitrage playbook.

Start Trading on CoinUnited.io

Create Your Free Account → — Trade crypto, stocks, forex, indices and commodities from one crypto-funded account. Leverage up to 2000x on selected products, subject to eligibility; fees are tiered by 30-day volume.